Lasa Supergenerics Ltd
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
- Market Cap ₹ 44.4 Cr.
- Current Price ₹ 8.99
- High / Low ₹ 25.6 / 8.16
- Stock P/E 92.6
- Book Value ₹ 11.2
- Dividend Yield 0.00 %
- ROCE -1.00 %
- ROE 1.01 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.80 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.16% over past five years.
- Company has a low return on equity of -9.72% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 95 | |
| 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 96 | |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -1 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | -1% | |
| 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -33 | |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 1 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 10 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -44 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -36 | |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -7.22 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | -20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 103% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -34% |
| 3 Years: | -30% |
| 1 Year: | -63% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | 6 |
| 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 7 | |
| 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 8 | |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
| 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 58 | |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 13 | |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 72 |
Cash Flows
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 | |
| 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 | 8 | |
| 0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 | -6 | |
| Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
Documents
Announcements
-
Board Meeting Intimation for For The Quarter Ended December 31, 2025
3 Feb - Board meeting Feb 13, 2026 to consider unaudited results for quarter ended Dec 31, 2025; trading window closed.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 15 Jan
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 02, 2026
1. Appointment Of Mr. Ganesh Suresh Potdar As An Additional Director In Capacity Of (Executive Director) And Occupier Of All Units Of The Company.
2 Jan - Appointed Ganesh Suresh Potdar as Executive Director/Occupier, effective Jan 02, 2026; term to Jan 01, 2030, subject to shareholder approval.
-
Closure of Trading Window
29 Dec 2025 - Trading window closed Jan 01, 2026 until 48 hours after unaudited results for quarter ended Dec 31, 2025.
-
Appointment of Company Secretary and Compliance Officer
15 Dec 2025 - Appointed Mrs. Mitti Jain as Company Secretary, Compliance Officer and KMP effective December 16, 2025.
Annual reports
Concalls
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptAI SummaryPPT
-
Jun 2020Transcript PPT
-
Jun 2018Transcript PPT
-
Feb 2018TranscriptAI SummaryPPT
-
Dec 2017Transcript PPT
Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production